Comparison of Presbyopia Between Glaucoma Patients Using Prostaglandin F Receptor Agonists and Fixed Combination Therapy.

IF 1.8 Q3 OPHTHALMOLOGY

Clinical Optometry Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI:10.2147/OPTO.S516392

Masahiko Ayaki, Akiko Hanyuda, Kazuno Negishi

{"title":"Comparison of Presbyopia Between Glaucoma Patients Using Prostaglandin F Receptor Agonists and Fixed Combination Therapy.","authors":"Masahiko Ayaki, Akiko Hanyuda, Kazuno Negishi","doi":"10.2147/OPTO.S516392","DOIUrl":null,"url":null,"abstract":"Objective: The purpose of this study was to compare the near add power among glaucoma patients using prostaglandin F (FP) receptor agonists and fixed combination therapies and controls.Methods: Participants were aged from 40 to 69 years and phakic with visual acuity of 20/25 or better, and included 2200 controls, 784 patients using FP receptor agonist for primary open-angle glaucoma (FP), and 412 patients using fixed combination (Combi). Each group was further divided into three groups based on age: those aged 40 to 49 years (40s), those aged 50 to 59 years (50s), and those aged 60 to 69 years (60s), and the near add power at 30 cm and various ophthalmic factors were compared.Results: The mean near add power for the control, FP, and Fixed combination groups were 1.21±0.66, 1.88±0.75 and 2.04±0.81 for those in their 40s, 2.16±0.59, 2.48±0.55 and 2.70±0.53 for those in their 50s, and 2.74±0.38, 2.89±0.35 and 2.97±0.17 for those in their 60s, respectively. Significant differences were found between all pairs of groups in all age groups (P<0.05, t-test). The odds ratios for near add power reaching 3.00 D were 4.8 (95% CI, 4.0-5.7) for glaucoma, 2.5 (2.1-3.0) for FP, and 6.0 (4.7-7.9) for the Fixed combination group, all of which were significant.Conclusion: The mean near add power of the Fixed combination group was higher than that of the control and FP groups for the same ages, indicating a faster progression of presbyopia.","PeriodicalId":43701,"journal":{"name":"Clinical Optometry","volume":"17 ","pages":"163-171"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Optometry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTO.S516392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The purpose of this study was to compare the near add power among glaucoma patients using prostaglandin F (FP) receptor agonists and fixed combination therapies and controls.

Methods: Participants were aged from 40 to 69 years and phakic with visual acuity of 20/25 or better, and included 2200 controls, 784 patients using FP receptor agonist for primary open-angle glaucoma (FP), and 412 patients using fixed combination (Combi). Each group was further divided into three groups based on age: those aged 40 to 49 years (40s), those aged 50 to 59 years (50s), and those aged 60 to 69 years (60s), and the near add power at 30 cm and various ophthalmic factors were compared.

Results: The mean near add power for the control, FP, and Fixed combination groups were 1.21±0.66, 1.88±0.75 and 2.04±0.81 for those in their 40s, 2.16±0.59, 2.48±0.55 and 2.70±0.53 for those in their 50s, and 2.74±0.38, 2.89±0.35 and 2.97±0.17 for those in their 60s, respectively. Significant differences were found between all pairs of groups in all age groups (P<0.05, t-test). The odds ratios for near add power reaching 3.00 D were 4.8 (95% CI, 4.0-5.7) for glaucoma, 2.5 (2.1-3.0) for FP, and 6.0 (4.7-7.9) for the Fixed combination group, all of which were significant.

Conclusion: The mean near add power of the Fixed combination group was higher than that of the control and FP groups for the same ages, indicating a faster progression of presbyopia.

Abstract Image

查看原文本刊更多论文

前列腺素F受体激动剂与固定联合治疗青光眼患者老花眼的比较。

目的：本研究的目的是比较前列腺素F受体激动剂和固定联合治疗和对照青光眼患者的近增加力。方法：参与者年龄在40 ~ 69岁之间，视力在20/25及以上，包括2200例对照，784例使用FP受体激动剂治疗原发性开角型青光眼（FP）， 412例使用固定联合（Combi）。每组按年龄进一步分为40 ~ 49岁（40s）、50 ~ 59岁（50s）、60 ~ 69岁（60s） 3组，比较30 cm近相加倍率及各项眼科因素。结果：40多岁对照组、FP组和Fixed组的平均近相加力分别为1.21±0.66、1.88±0.75和2.04±0.81,50多岁组为2.16±0.59、2.48±0.55和2.70±0.53,60多岁组为2.74±0.38、2.89±0.35和2.97±0.17。各年龄组各对组间差异均有统计学意义（p检验）。青光眼接近增加功率达到3.00 D的比值比为4.8 (95% CI, 4.0-5.7)， FP为2.5 (2.1-3.0)，Fixed联合组为6.0(4.7-7.9)，均具有显著性。结论：固定联合组老花眼的平均近加法力高于对照组和FP组，老花眼进展更快。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Optometry OPHTHALMOLOGY-

CiteScore

3.00

自引率

5.90%

发文量

审稿时长

16 weeks

期刊介绍： Clinical Optometry is an international, peer-reviewed, open access journal focusing on clinical optometry. All aspects of patient care are addressed within the journal as well as the practice of optometry including economic and business analyses. Basic and clinical research papers are published that cover all aspects of optics, refraction and its application to the theory and practice of optometry. Specific topics covered in the journal include: Theoretical and applied optics, Delivery of patient care in optometry practice, Refraction and correction of errors, Screening and preventative aspects of eye disease, Extended clinical roles for optometrists including shared care and provision of medications, Teaching and training optometrists, International aspects of optometry, Business practice, Patient adherence, quality of life, satisfaction, Health economic evaluations.